Your browser doesn't support javascript.
loading
Pulmonary Function Testing Pre-heart Transplant Predicts Posttransplant Survival.
Lundgren, Scott W; Lowes, Brian D; Lyden, Elizabeth; Zolty, Ronald; Burdorf, Adam; Hyden, Marshall; Um, John; Stoller, Douglas A.
Afiliação
  • Lundgren SW; Department of Internal Medicine, Division of Cardiology, University of Nebraska Medical Center, Omaha, NE.
  • Lowes BD; Department of Internal Medicine, Division of Cardiology, University of Nebraska Medical Center, Omaha, NE.
  • Lyden E; College of Public Health, University of Nebraska Medical Center, Omaha, NE.
  • Zolty R; Department of Internal Medicine, Division of Cardiology, University of Nebraska Medical Center, Omaha, NE.
  • Burdorf A; Department of Internal Medicine, Division of Cardiology, University of Nebraska Medical Center, Omaha, NE.
  • Hyden M; Department of Internal Medicine, Division of Cardiology, University of Nebraska Medical Center, Omaha, NE.
  • Um J; Department of Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE.
  • Stoller DA; Department of Internal Medicine, Division of Cardiology, University of Nebraska Medical Center, Omaha, NE.
Transplant Direct ; 7(10): e752, 2021 Oct.
Article em En | MEDLINE | ID: mdl-34514107
ABSTRACT
Although pulmonary function testing (PFT) is typically performed for heart transplant evaluation, the prognostic utility of PFTs after transplantation is unknown. We evaluated whether PFT parameters were correlated with outcomes following heart transplantation.

METHODS:

International Society for Heart and Lung Transplantation Thoracic Organ Transplant Registry data were utilized. Survival was assessed using Kaplan-Meier method and compared via log-rank test. Cox proportional hazard modeling was used to evaluate univariate and multivariate predictors of survival.

RESULTS:

Eight hundred two patients pretransplant PFT data were available for evaluation. Forced expiratory volume in 1 s (FEV1) < 50% predicted (P < 0.0001), and forced vital capacity (FVC) < 50% predicted each had significantly higher mortality (P = 0.001) compared with patients with FEV1 or FVC 50%-80% or >80%. FEV1/FVC < 0.7 was not associated with increased mortality. FEV1 and FVC below 50% both predicted longer lengths of stay (P = 0.028 for FEV1 and P = 0.0075 for FVC). After adjusting for male gender, age, body mass index, smoking history, chronic obstructive pulmonary disease, creatinine, albumin, and total bilirubin, FEV1 < 50% (hazard ratio, 4.91; P < 0.0001; 95% confidence interval, 2.69-8.94) and FVC < 50% (hazard ratio, 2.75; P = 0.003; 95% confidence interval, 1.4-5.4) both remained independent predictors of mortality.

CONCLUSIONS:

Abnormal pulmonary function (FEV1 or FVC below 50% of predicted) pre-heart transplantation is associated with increased mortality and longer lengths of stay posttransplant.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transplant Direct Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Níger

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transplant Direct Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Níger